search

All clinical trials

Results 460321-460330 of 470744

Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric...

Multiple Myeloma

The purpose of this individual-patient investigational new drug (IND) single patient request (SPR) is to provide participants treatment with JNJ-68284528, an investigational product prior to its marketing authorization. Such access may be considered for participants with serious/life-threatening diseases or conditions, where there exists no alternative treatments or where alternative treatments have been exhausted.

No longer available0 enrollment criteria

Canakinumab MAP in COVID-19 Pneumonia With CRS

Cytokine Release Syndrome in COVID-19-induced Pneumonia

This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia

No longer available11 enrollment criteria

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

COVID19

This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Approved for marketing16 enrollment criteria

Expanded Access for BLZ-100 (Tozuleristide)

This is the Blaze Bioscience expanded access program for its investigational drug tozuleristide intended for patients with life-threatening diseases or conditions who have exhausted approved treatment options and are unable to participate in a clinical trial involving the investigational drug tozuleristide.

Available2 enrollment criteria

Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program

COVID-19

This is an expanded access treatment protocol to treat up to 100 patients with severe or life-threatening, laboratory confirmed COVID-19 with COVID-19 convalescent plasma.

No longer available18 enrollment criteria

Expanded Access to Epcoritamab

Lymphoma

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to epcoritamab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

No longer available1 enrollment criteria

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene...

Mantle Cell LymphomaAcute Lymphoblastic Leukemia

The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.

Available9 enrollment criteria

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome...

Hunter Syndrome

This post-trial access program is to allow continued access for people who participated and are benefitting from treatment on the HGT-HIT-046 (NCT01506141) or SHP609-302 (NCT02412787) studies, which will be closed down. Idursulfase-IT also known as TAK-609, is a medicine to help treat Hunter Syndrome and issues with remembering, learning new things, and concentrating, also called cognitive impairment.

Available4 enrollment criteria

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Cancer

This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and/or wish to continue treatment, and who are eligible for treatment under this expanded access study.

Available2 enrollment criteria

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Urothelial Cancer of Renal PelvisUrothelial Carcinoma of the Renal Pelvis and Ureter4 more

This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.

Available1 enrollment criteria
1...460324603346034...47075

Need Help? Contact our team!


We'll reach out to this number within 24 hrs